In a prospective, multi-centered randomized controlled trial (RCT) involving 100+ patients, wound care physicians evaluated the impact of Mirragen, a borate-based bioactive glass fiber matrix, in the treatment of diabetic foot ulcers (DFUs). The second RCT on DFUs sponsored by Engineered Tissue Solutions (ETS) further illustrates Mirragen’s ability to facilitate the wound healing process in these challenging wounds. 

Join us for our webinar, where top wound care experts will delve into the study’s details and explore why Mirragen is an essential addition to your wound care armamentarium.

This is a non-CME event. By registering for this program, you consent to share your registration information with the program's sponsor.